Fundraising Fox

Progentos Therapeutics

4 known investors

progentos.com ↗

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.

BiotechDeep TechMedical Devices

Investors · 4

Alta PartnersJackson
Longwood FundBoston
Mission BiocapitalSan Francisco · $500K – $500K
Dolby Family VenturesreportedSan Francisco

In the news